Acquisition
Roche Acquires CAR-T Partner Poseida Therapeutics for $1 Billion Upfront
Roche, Poseida Therapeutics, CAR-T, cell therapy, acquisition, biotechnology, pharmaceuticals
Halozyme Therapeutics Abandons $2.1 Billion Acquisition Bid for Evotec Due to Lack of Engagement
Halozyme Therapeutics, Evotec, acquisition bid, withdrawal, lack of engagement, biotech industry
BioNTech Acquires Biotheus for $800M to Enhance Oncology Strategy with Promising Bispecific Antibody
BioNTech, Biotheus, oncology, bispecific antibody, BNT327/PM8002, PD-L1, VEGF-A, cancer treatment, acquisition
UnitedHealth’s Optum Defends $3.3 Billion Acquisition of Amedisys Amid DOJ Lawsuit
Optum, Amedisys, UnitedHealth, DOJ, Acquisition, Healthcare, Antitrust
ALK-Abell Acquires Epinephrine Nasal Spray for $145 Million
ALK-Abell, Epinephrine Nasal Spray, Acquisition, Pharmaceutical Portfolio
Catalent Misses Revenue Estimates Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition
Catalent, Novo Holdings, Acquisition, Revenue Estimates, Pharmaceutical Market, Competition, FTC, Antitrust
Catalent Falls Short of Q1 Revenue Projections Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition
Catalent, Q1 Revenue, Novo Holdings, Acquisition, Pharmaceutical Industry, Contract Manufacturing
EU Regulators Schedule December 6 Decision on Novo Holdings’ Acquisition of Catalent
EU regulators, Novo Holdings, Catalent, acquisition, antitrust review, December 6 deadline
Ocuphire Pharma Acquires Opus Genetics, Expanding into Inherited Retinal Disease Gene Therapies
Ocuphire Pharma, Opus Genetics, gene therapy, inherited retinal diseases (IRDs), merger, acquisition, biopharmaceutical, ophthalmic treatments
Vanda Pharmaceuticals Rejects Cycle’s Second Takeover Bid Amid FDA Rejection of Tradipitant
Vanda Pharmaceuticals, Cycle Pharmaceuticals, takeover bid, FDA rejection, tradipitant, gastroparesis, biopharma, acquisition offer